Economics of treating drug-resistant tuberculosis
Following recent scientific successes from the Nix-TB, TB-PRACTECAL and ZeNix trials, the World Health Organization has announced forthcoming changes to treatment guidelines for rifampicin resistant tuberculosis, to include new short-course, all-oral treatment regimens including bedaquiline, pretomanid, and linezolid.
In the context of this forthcoming change, countries are considering the potential costs and benefits of these new regimens. Four panelists will present their findings from recent economic evaluations on short-course all-oral treatment regimens and discuss potential policy implications of study results.
- Sedona Sweeney, LSHTM
- Gabriela Gomez, International AIDS Vaccine Initiative
- Lyndon James, Harvard University
- Hojoon Sohn, Seoul National University
Please note that the recording link will be listed on this page when available